Observations placeholder
Promacta
Identifier
019871
Type of Spiritual Experience
Background
A description of the experience
Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Designated an orphan drug in the USA and European Union, it is under the trade name Promacta in the USA and is marketed as Revolade in the EU. Eltrombopag was approved by the U.S. Food and Drug Administration on November 20, 2008 Eltrombopag received FDA breakthrough treatment designation in February 2014 for patients with aplastic anemia for which immunosuppression has not been successful [sic]. It has been shown to produce a trilineage hematopoesis in some patients with aplastic anemia, resulting in increased platelet counts, along with red and white blood cell counts.
On Jan, 29, 2016: 2,810 people reported to have side effects when taking Promacta. Among them, 1 people (0.04%) has Hallucination.
On Jan, 29, 2016: 2,810 people reported to have side effects when taking Promacta. Among them, 433 people (15.41%) have Death.
Time on Promacta when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 19.44% | 50.93% | 13.89% | 12.04% | 3.70% | 0.00% | 0.00% |
Gender of people who have Death when taking Promacta :
| Female | Male | |
| Death | 49.65% | 50.35% |
Age of people who have Death when taking Promacta :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 0.27% | 0.55% | 4.40% | 11.81% | 82.97% |
Top conditions involved for these people :
- Idiopathic thrombocytopenic purpura (257 people, 59.35%)
- Thrombocytopenia (29 people, 6.70%)
- Autoimmune thrombocytopenia (19 people, 4.39%)
- Myelodysplastic syndrome (9 people, 2.08%)
- Hepatitis c (4 people, 0.92%)